Skip to main content
. 2012 Apr 4;7(4):e34850. doi: 10.1371/journal.pone.0034850

Figure 2. TOX2 expression in normal and cancer cells.

Figure 2

(A) Genomic structure of TOX2. Top box: Predicted transcript variants of TOX2 (var.1-4) currently used as reference sequence for Homo sapiens chromosome 20, GRCh37.p2, (GenBank accession number NC_000020.10). Bottom box: Transcripts sequenced from human cells (var.5 and 6). Small arrows indicate the location and direction of primer binding sites; T#F or T#R (forward or reverse primers for TaqMan assays) and G#F or G#R (forward or reverse primers for gel-based assays). (B) Expression of TOX2 transcript variants 5 and 6 and the house keeping gene beta-actin in distant normal lung tissue (DNLT), HBEC, and various lung and breast cancer cell lines. In Vehicle-treated (S, for sham) lung cancer (H1838, H2009) and breast cancer (T47D) cell lines with methylated promoter CpG island, both transcripts were silenced and expression of both was primarily restored with 5-Aza-2′-deoxycytidne (D) but not trichostatin A (T) treatment. (C and D) TaqMan assays that use distinct primer sets from those used for gel-based assays confirmed results shown in Figure 2B. (C) Expression of TOX2 var.5 or both (var.5 & 6) in lung tumors (n = 20) relative to DNLT (n = 10) obtained from NSCLC patients. (D) Expression of TOX2 var.5 or both (var.5+6) in TSA or DAC treated lung and breast cancer cell lines relative to Vehicle-treated (Sham) cell lines.